Literature DB >> 33736624

Early surgery with antibiotic medication was effective and efficient in treating pyogenic spondylodiscitis.

Wei Guo1,2, Min Wang3, Guangfu Chen3, Kuan-Hung Chen1,2, Yong Wan1,2, Bailing Chen1,2, Xuenong Zou1,2, Xinsheng Peng4,5.   

Abstract

BACKGROUND: Pyogenic spondylodiscitis (PSD) is challenging to the orthopedist with regards to diagnosis and treatment. The present study was designed to assess and suggest the most indicative diagnostic method and evaluate the effect of surgery comprising of debridement, instrumentation and fusion in treating PSD.
METHODS: Seventy-six patients with PSD who underwent surgical intervention were retrospectively enrolled. Their medical documents, corrections of spinal alignment and improvements in neurological function were assessed. Surgical approaches were compared in lumbar surgeries regarding the improvements in lordotic angle and neurological function.
RESULTS: Elevated c-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) were found in 77.6 and 71.1% patients respectively. Infectious lesions were found at lumbar (85.5%), cervical (10.5%) and thoracic (3.9%), ascertained with contrast-enhanced MRI. For lumbar patients, surgery was performed through the anterior (26.2%), posterior (49.2%) or combined approach (24.6%), and differences in improvement of lordosis and neurological function between each approach were insignificant. The pathogen was identified in 22.4% of the patients. Postoperative antibiotic therapy was managed against the result of susceptibility test, or empirically given to patients with negative cultures. All antibiotic therapy was initiated intravenously for 4-6 weeks and orally for 6 weeks.
CONCLUSION: Elevated CRP and/or ESR, with focal hyper-intensity on contrast-enhanced MRI are suggestive of possible PSD. Surgical intervention comprising of debridement, short-segment instrumentation and fusion that early applied to the PSD patients followed by postoperative antibiotic therapy have demonstrated preferable outcomes, but require further study. THE TRANSLATIONAL POTENTIAL OF THIS ARTICLE: This article advocates early surgery to enable prompt diagnosis and treatment of PSD, and thus guarantee favorable outcomes for patients, as is shown in our study. In addition, different surgical approaches to the lesions were compared and discussed in this manuscript, but no differences in outcome between approaches were found. This suggests that thorough debridement should be prioritized over selection of surgical approach. In summary, this article has large translational potential to be applied clinically.

Entities:  

Keywords:  Antibiotic; Laboratory test; Pyogenic spondylodiscitis; Radiology; Surgery

Mesh:

Substances:

Year:  2021        PMID: 33736624      PMCID: PMC7977180          DOI: 10.1186/s12891-021-04155-2

Source DB:  PubMed          Journal:  BMC Musculoskelet Disord        ISSN: 1471-2474            Impact factor:   2.362


  47 in total

1.  Vertebral osteomyelitis: long-term outcome for 253 patients from 7 Cleveland-area hospitals.

Authors:  Martin C McHenry; Kirk A Easley; Geri A Locker
Journal:  Clin Infect Dis       Date:  2002-04-22       Impact factor: 9.079

2.  Anterior versus posterior fixation for the treatment of lumbar pyogenic vertebral osteomyelitis.

Authors:  Meng Si; Zhi-Ping Yang; Zhen-Feng Li; Qiang Yang; Jian-Min Li
Journal:  Orthopedics       Date:  2013-06       Impact factor: 1.390

3.  Decompression alone versus fusion for pyogenic spondylodiscitis.

Authors:  Sung Hyun Noh; Ho Yeol Zhang; Hyun Sun Lim; Hyeon Jin Song; Kyung Hwa Yang
Journal:  Spine J       Date:  2017-04-13       Impact factor: 4.166

4.  Nontuberculous pyogenic spinal infection in adults: a 12-year experience from a tertiary referral center.

Authors:  Joseph S Butler; Martin J Shelly; Marcus Timlin; William G Powderly; John M O'Byrne
Journal:  Spine (Phila Pa 1976)       Date:  2006-11-01       Impact factor: 3.468

5.  Failure modes in conservative and surgical management of infectious spondylodiscitis.

Authors:  Kestutis Valancius; Ebbe Stender Hansen; Kristian Høy; Peter Helmig; Bent Niedermann; Cody Bünger
Journal:  Eur Spine J       Date:  2012-12-18       Impact factor: 3.134

6.  Increasing incidence of pyogenic spondylodiscitis: a 14-year population-based study.

Authors:  Michala Kehrer; Court Pedersen; Thøger G Jensen; Annmarie T Lassen
Journal:  J Infect       Date:  2013-12-01       Impact factor: 6.072

7.  Evaluation of conservative treatment of non specific spondylodiscitis.

Authors:  N Bettini; M Girardo; E Dema; S Cervellati
Journal:  Eur Spine J       Date:  2009-05-05       Impact factor: 3.134

8.  Is switching to an oral antibiotic regimen safe after 2 weeks of intravenous treatment for primary bacterial vertebral osteomyelitis?

Authors:  Baharak Babouee Flury; Luigia Elzi; Marko Kolbe; Reno Frei; Maja Weisser; Stefan Schären; Andreas F Widmer; Manuel Battegay
Journal:  BMC Infect Dis       Date:  2014-04-27       Impact factor: 3.090

9.  Pyogenic vertebral osteomyelitis of the elderly: Characteristics and outcomes.

Authors:  Johan Courjon; Adrien Lemaignen; Idir Ghout; Audrey Therby; Nadia Belmatoug; Aurélien Dinh; Guillaume Gras; Louis Bernard
Journal:  PLoS One       Date:  2017-12-05       Impact factor: 3.240

10.  Discrimination of pyogenic spondylitis from brucellar spondylitis on MRI.

Authors:  Tao Li; Wei Li; Yong Du; Meng Gao; Xiaoyang Liu; Guodong Wang; Haomin Cui; Zhensong Jiang; Xingang Cui; Jianmin Sun
Journal:  Medicine (Baltimore)       Date:  2018-06       Impact factor: 1.889

View more
  2 in total

1.  Osteomyelitis of the spine: treatments and future directions.

Authors:  Yusuf Mehkri; Patrick Felisma; Eric Panther; Brandon Lucke-Wold
Journal:  Infect Dis Res       Date:  2022-01-24

Review 2.  Minimally Invasive Spine Stabilization for Pyogenic Spondylodiscitis: A 23-Case Series and Review of Literature.

Authors:  Shinichi Ishihara; Haruki Funao; Norihiro Isogai; Masayuki Ishihara; Takanori Saito; Ken Ishii
Journal:  Medicina (Kaunas)       Date:  2022-06-01       Impact factor: 2.948

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.